Free Trial
→ The roadshow starts Monday. This stock isn't ready. (From Behind the Markets) (Ad)tc pixel Free PHAR Stock Alerts

Pharming Group (PHAR) Financials

Pharming Group logo
$12.28 -0.31 (-2.46%)
Closing price 04:00 PM Eastern
Extended Trading
$12.25 -0.03 (-0.25%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Pharming Group

Annual Income Statements for Pharming Group

This table shows Pharming Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 29 41 38 16 14 -11 -12 2.54
Consolidated Net Income / (Loss)		 29 41 38 16 14 -11 -12 2.54
Net Income / (Loss) Continuing Operations		 29 41 38 16 14 -11 -12 2.54
Total Pre-Tax Income 		0.98 52 44 23 15 -12 -8.49 13
Total Operating Income		 44 68 76 14 18 -25 -5.72 22
Total Gross Profit		 129 165 189 178 188 220 262 331
Total Revenue		 116 190 212 199 206 125 183 248
Operating Revenue		 116 190 212 199 206 125 183 248
Total Cost of Revenue		 25 24 23 21 18 25 35 46
Operating Cost of Revenue		 25 24 24 21 18 25 35 46
Total Operating Expenses		 47 98 114 167 184 125 154 180
Selling, General & Admin Expense		 14 21 24 37 46 56 71 80
Research & Development Expense		 33 32 39 70 53 69 83 100
Total Other Income / (Expense), net		 -43 -16 -33 8.82 -2.16 13 -2.78 -9.27
Other Income / (Expense), net		 -43 -16 -30 12 11 13 -2.78 -9.27
Income Tax Expense		 -28 12 6.35 7.08 1.31 -1.46 3.35 10
Basic Earnings per Share		 $0.04 $0.07 $0.06 $0.03 $0.02 ($0.02) ($0.02) $0.00
Weighted Average Basic Shares Outstanding		 - - 638.82M 648.75M 656.35M 671.07M 680.31M 701.68M
Diluted Earnings per Share		 $0.04 $0.06 $0.06 $0.02 $0.02 ($0.02) ($0.02) $0.00
Weighted Average Diluted Shares Outstanding		 - - 638.82M 648.75M 656.35M 671.07M 680.31M 701.68M
Weighted Average Basic & Diluted Shares Outstanding		 - - 638.82M 648.75M 656.35M 671.07M 680.31M 701.68M

Quarterly Income Statements for Pharming Group

No quarterly income statements for Pharming Group are available.

Annual Cash Flow Statements for Pharming Group

This table details how cash moves in and out of Pharming Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 21 -135 174 -71 14 -121 120 78
Net Cash From Operating Activities		 46 -78 256 -31 16 -120 16 49
Net Cash From Continuing Operating Activities		 46 -78 256 -31 16 -120 16 55
Net Income / (Loss) Continuing Operations		 0.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Depreciation Expense		 7.51 5.80 8.31 20 13 16 16 11
Non-Cash Adjustments To Reconcile Net Income		 44 -81 248 -51 -12 -133 9.34 28
Changes in Operating Assets and Liabilities, net		 -6.34 -2.68 -0.02 0.73 14 -2.31 -9.55 9.53
Net Cash From Investing Activities		 -4.31 -2.65 -4.66 -15 -1.38 -1.44 -0.79 28
Net Cash From Continuing Investing Activities		 -2.86 -2.65 -4.66 -15 -1.38 -1.44 -0.79 26
Acquisitions		 - - - - - - - -57
Purchase of Investments		 0.00 0.00 0.00 -4.59 - - - -0.00
Sale and/or Maturity of Investments		 - - - - - - - 85
Net Cash From Financing Activities		 -21 -55 -78 -25 0.00 0.00 105 1.50
Net Cash From Continuing Financing Activities		 -20 -55 -78 -25 0.00 0.00 105 1.50
Cash Interest Received		 - 1.13 0.72 0.05 0.09 2.88 5.20 2.07

Quarterly Cash Flow Statements for Pharming Group

No quarterly cash flow statements for Pharming Group are available.

Annual Balance Sheets for Pharming Group

This table presents Pharming Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 256 418 397 426 463 400 500
Total Current Assets		 119 263 249 278 316 278 299
Cash & Equivalents		 74 205 192 207 62 55 145
Restricted Cash		 0.00 1.00 0.23 0.21 - 0.00 0.76
Short-Term Investments		 - - - - - 113 34
Accounts Receivable		 29 36 30 28 46 55 55
Inventories, net		 16 21 27 42 57 56 65
Plant, Property, & Equipment, net		 9.59 12 13 10 9.69 7.75 6.05
Plant, Property & Equipment, gross		 9.59 12 13 10 9.69 7.75 6.05
Total Noncurrent Assets		 127 143 106 131 131 114 193
Long-Term Investments		 6.18 7.12 1.45 2.90 4.31 0.47 1.94
Intangible Assets		 79 94 84 75 71 61 136
Noncurrent Deferred & Refundable Income Taxes		 32 32 - 23 30 31 31
Other Noncurrent Operating Assets		 9.25 9.94 21 30 25 22 25
Total Liabilities & Shareholders' Equity		 256 418 397 426 463 400 500
Total Liabilities		 139 235 204 221 244 179 222
Total Current Liabilities		 114 77 47 60 78 67 106
Accounts Payable		 41 48 42 54 73 67 106
Total Noncurrent Liabilities		 24 158 158 161 166 112 116
Long-Term Debt		 0.00 150 139 133 138 82 98
Capital Lease Obligations		 4.89 8.23 18 30 30 30 18
Total Equity & Noncontrolling Interests		 799 775 193 205 219 221 277
Total Preferred & Common Equity		 117 183 193 205 219 221 277
Total Common Equity		 357 328 -262 -258 -260 221 277
Common Stock		 7.23 7.31 7.43 7.51 7.67 7.77 8.01
Retained Earnings		 341 296 -273 -256 -265 -275 -273
Other Equity Adjustments		 8.93 25 3.40 -8.74 -2.06 489 542

Quarterly Balance Sheets for Pharming Group

No quarterly balance sheets for Pharming Group are available.

Annual Metrics And Ratios for Pharming Group

This table displays calculated financial ratios and metrics derived from Pharming Group's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - 701,680,440.00
DEI Adjusted Shares Outstanding		 - - - - - - - 701,680,440.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - 0.00
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 63.78% 11.74% -6.27% 3.39% -39.38% 138.44% 35.13%
EBITDA Growth		 0.00% 587.34% -7.15% -16.57% -5.52% -90.84% 21.77% 217.52%
EBIT Growth		 0.00% 5,256.41% -12.72% -44.21% 15.35% -140.70% 5.89% 251.27%
NOPAT Growth		 0.00% -95.83% 23.36% -85.60% 76.98% -206.72% 66.01% 209.16%
Net Income Growth		 0.00% 41.78% -6.93% -57.62% -14.52% -177.14% -12.26% 121.43%
EPS Growth		 0.00% 57.89% -8.33% -58.18% -17.39% -184.21% -12.50% 122.22%
Operating Cash Flow Growth		 0.00% -267.23% 430.42% -111.92% 151.47% -862.56% 113.24% 207.55%
Free Cash Flow Firm Growth		 0.00% 0.00% 170.06% -66.02% -138.58% -722.71% 95.20% -570.28%
Invested Capital Growth		 0.00% 0.00% 40.14% -0.09% 15.61% 8.28% -2.82% 27.91%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - -
Gross Margin		 111.51% 87.14% 88.91% 89.37% 91.46% 176.59% 88.09% 133.35%
EBITDA Margin		 7.32% 30.72% 25.53% 22.73% 20.77% 3.14% 1.60% 9.70%
Operating Margin		 37.52% 35.94% 35.94% 6.82% 8.87% -20.35% -2.90% 8.92%
EBIT Margin		 0.85% 27.67% 21.61% 12.86% 14.35% -9.64% -3.80% 5.18%
Profit (Net Income) Margin		 24.67% 21.36% 17.79% 8.04% 6.65% -8.46% -3.98% 1.02%
Tax Burden Percent		 2,916.34% 77.54% 85.60% 69.31% 91.24% 87.81% 139.44% 19.76%
Interest Burden Percent		 100.00% 99.55% 96.16% 90.20% 50.79% 100.00% 75.12% 100.01%
Effective Tax Rate		 -2,816.34% 22.46% 14.40% 30.69% 8.76% 0.00% 0.00% 80.25%
Return on Invested Capital (ROIC)		 0.00% 113.95% 58.53% 7.22% 11.87% -11.34% -3.76% 2.32%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 117.45% 62.61% 5.36% 16.92% -24.41% 6.01% 5.32%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -103.80% -53.74% -3.92% -4.99% 6.36% -1.62% -1.30%
Return on Equity (ROE)		 0.00% 10.15% 4.80% 3.31% 6.88% -4.98% -5.38% 1.02%
Cash Return on Invested Capital (CROIC)		 0.00% -86.05% 25.11% 7.31% -2.62% -19.29% -0.90% -22.17%
Operating Return on Assets (OROA)		 0.00% 20.53% 13.60% 6.27% 7.17% -2.70% -2.62% 2.85%
Return on Assets (ROA)		 0.00% 15.85% 11.19% 3.92% 3.32% -2.37% -2.74% 0.56%
Return on Common Equity (ROCE)		 0.00% 4.54% 2.09% 0.22% -9.00% 6.09% 6.46% 1.02%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 34.55% 20.58% 8.29% 6.68% -4.82% -5.36% 0.00%
Net Operating Profit after Tax (NOPAT)		 1,269 53 65 9.40 17 -18 -6.03 4.37
NOPAT Margin		 1,094.35% 27.87% 30.77% 4.73% 8.09% -14.24% -2.03% 1.76%
Net Nonoperating Expense Percent (NNEP)		 0.00% -3.50% -4.08% 1.87% -5.06% 13.07% -9.77% -3.00%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - 4.52% -4.59% -1.83% 1.11%
Cost of Revenue to Revenue		 21.90% 12.73% 11.06% 10.57% 8.54% 20.23% 10.23% 18.35%
SG&A Expenses to Revenue		 12.07% 11.16% 11.35% 18.59% 22.38% 44.83% 23.77% 32.25%
R&D to Revenue		 28.51% 16.74% 18.15% 35.38% 25.55% 55.29% 27.98% 40.48%
Operating Expenses to Revenue		 40.58% 51.46% 53.83% 83.87% 89.65% 100.12% 91.72% 72.73%
Earnings before Interest and Taxes (EBIT)		 0.98 53 46 26 30 -12 -11 13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 8.49 58 54 45 43 3.91 4.77 24
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.03 0.04 0.00 0.00 0.00 0.00 4.34
Price to Tangible Book Value (P/TBV)		 0.00 0.04 0.06 0.00 0.00 0.00 0.00 8.49
Price to Revenue (P/Rev)		 0.09 0.06 0.06 2.87 3.48 6.02 2.27 4.85
Price to Earnings (P/E)		 0.38 0.27 0.36 35.70 52.33 0.00 0.00 473.64
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 262.73% 372.51% 276.07% 2.80% 1.91% 0.00% 0.00% 0.21%
Enterprise Value to Invested Capital (EV/IC)		 0.00 4.61 3.13 7.63 7.52 8.17 7.70 5.38
Enterprise Value to Revenue (EV/Rev)		 0.00 2.26 1.92 4.99 5.50 10.67 4.10 4.58
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 7.34 7.52 21.95 26.48 340.03 255.69 47.21
Enterprise Value to EBIT (EV/EBIT)		 0.00 8.15 8.89 38.78 38.31 0.00 0.00 88.44
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 8.09 6.24 105.55 67.96 0.00 0.00 260.16
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 1.59 0.00 71.96 0.00 76.82 23.29
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 14.56 104.29 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.07 0.21 0.83 0.80 0.77 0.49 0.42
Long-Term Debt to Equity		 0.00 0.01 0.20 0.82 0.80 0.77 0.49 0.42
Financial Leverage		 0.00 -0.88 -0.86 -0.73 -0.29 -0.26 -0.27 -0.25
Leverage Ratio		 0.00 0.32 0.43 0.84 2.07 2.10 1.96 1.81
Compound Leverage Factor		 0.00 0.32 0.41 0.76 1.05 2.10 1.47 1.81
Debt to Total Capital		 0.00% 6.55% 17.12% 45.23% 44.37% 43.43% 33.10% 29.47%
Short-Term Debt to Total Capital		 0.00% 5.98% 0.22% 0.53% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.57% 16.90% 44.70% 44.37% 43.43% 33.10% 29.47%
Preferred Equity to Total Capital		 0.00% 51.70% 47.84% 129.24% 125.67% 123.72% 147.99% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 41.75% 35.04% -74.47% -70.04% -67.14% -81.09% 70.53%
Debt to EBITDA		 0.00 0.96 2.95 3.53 3.82 42.92 22.95 4.81
Net Debt to EBITDA		 0.00 -0.42 -0.98 -0.76 -1.11 26.04 11.32 -2.74
Long-Term Debt to EBITDA		 0.00 0.08 2.92 3.48 3.82 42.92 22.95 4.81
Debt to NOPAT		 0.00 1.06 2.45 16.95 9.81 -9.46 -18.12 26.51
Net Debt to NOPAT		 0.00 -0.46 -0.82 -3.64 -2.84 -5.74 -8.94 -15.12
Long-Term Debt to NOPAT		 0.00 0.09 2.42 16.75 9.81 -9.46 -18.12 26.51
Altman Z-Score		 0.00 3.35 2.43 2.04 2.42 1.84 2.56 3.53
Noncontrolling Interest Sharing Ratio		 0.00% 55.33% 56.50% 93.26% 230.80% 222.17% 219.95% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 1.05 3.43 5.33 4.65 4.06 3.77 2.83
Quick Ratio		 0.00 0.90 3.14 4.74 3.94 1.38 1.49 2.21
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -40 28 9.51 -3.67 -30 -1.45 -42
Operating Cash Flow to CapEx		 1,622.92% -2,929.09% 5,501.14% -284.25% 1,141.79% -8,337.23% 2,007.72% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.74 0.63 0.49 0.50 0.28 0.69 0.55
Accounts Receivable Turnover		 0.00 6.58 6.55 6.04 7.14 3.38 5.89 4.53
Inventory Turnover		 0.00 1.49 1.26 0.87 0.50 0.51 0.54 0.75
Fixed Asset Turnover		 0.00 19.80 19.45 15.63 17.42 12.41 34.08 35.94
Accounts Payable Turnover		 0.00 0.59 0.53 0.47 0.36 0.40 0.44 0.53
Days Sales Outstanding (DSO)		 0.00 55.49 55.71 60.46 51.12 108.02 62.01 80.62
Days Inventory Outstanding (DIO)		 0.00 245.07 290.66 420.64 723.64 717.25 675.07 483.83
Days Payable Outstanding (DPO)		 0.00 614.01 686.70 782.31 1,007.36 919.25 835.04 691.94
Cash Conversion Cycle (CCC)		 0.00 -313.46 -340.33 -301.21 -232.59 -93.98 -97.96 -127.49
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 93 130 130 150 163 158 211
Invested Capital Turnover		 0.00 4.09 1.90 1.53 1.47 0.80 1.85 1.32
Increase / (Decrease) in Invested Capital		 0.00 93 37 -0.11 20 12 -4.58 46
Enterprise Value (EV)		 0.00 428 408 992 1,131 1,331 1,218 1,136
Market Capitalization		 11 11 14 571 716 750 675 1,202
Book Value per Share		 $0.00 $396.61 $0.51 ($0.41) ($0.39) ($0.40) ($0.40) $0.41
Tangible Book Value per Share		 $0.00 $308.36 $0.37 ($0.54) ($0.51) ($0.50) ($0.49) $0.21
Total Capital		 0.00 855 935 352 368 387 330 393
Total Debt		 0.00 56 160 159 163 168 109 116
Total Long-Term Debt		 0.00 4.89 158 157 163 168 109 116
Net Debt		 0.00 -25 -53 -34 -47 102 54 -66
Capital Expenditures (CapEx)		 2.86 2.65 4.66 11 1.38 1.44 0.79 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -18 -18 12 10 177 150 14
Debt-free Net Working Capital (DFNWC)		 0.00 56 188 205 218 238 205 194
Net Working Capital (NWC)		 0.00 5.18 186 203 218 238 205 194
Net Nonoperating Expense (NNE)		 1,240 12 28 -6.60 2.96 -7.21 5.81 1.83
Net Nonoperating Obligations (NNO)		 0.00 -706 -645 -63 -54 -56 -63 -66
Total Depreciation and Amortization (D&A)		 7.51 5.80 8.31 20 13 16 16 11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -9.50% -8.37% 6.24% 4.98% 141.71% 50.37% 5.53%
Debt-free Net Working Capital to Revenue		 0.00% 29.65% 88.80% 102.86% 105.92% 191.25% 68.86% 78.07%
Net Working Capital to Revenue		 0.00% 2.73% 87.84% 101.91% 105.92% 191.25% 68.86% 78.07%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.05 $0.00 $0.02 ($0.02) ($0.02) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 638.82M 0.00 656.35M 671.07M 680.31M 701.68M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.05 $0.00 $0.02 ($0.02) ($0.02) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 638.82M 0.00 656.35M 671.07M 680.31M 701.68M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 638.82M 0.00 656.35M 671.07M 680.31M 701.68M
Normalized Net Operating Profit after Tax (NOPAT)		 30 53 65 9.40 17 -18 -6.03 15
Normalized NOPAT Margin		 26.27% 27.87% 30.77% 4.73% 8.09% -14.24% -2.03% 6.24%
Pre Tax Income Margin		 0.85% 27.55% 20.78% 11.60% 7.29% -9.64% -2.86% 5.18%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Pharming Group

No quarterly metrics and ratios for Pharming Group are available.


Financials Breakdown Chart

Pharming Group Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Pharming Group's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Pharming Group's net income appears to be on a downward trend, with a most recent value of $2.54 million in 2025, falling from $28.60 million in 2018. The previous period was -$11.84 million in 2024. View Pharming Group's forecast to see where analysts expect Pharming Group to go next.

Pharming Group's total operating income in 2025 was $22.11 million, based on the following breakdown:
  • Total Gross Profit: $330.63 million
  • Total Operating Expenses: $180.33 million

Over the last 7 years, Pharming Group's total revenue changed from $115.93 million in 2018 to $247.94 million in 2025, a change of 113.9%.

Pharming Group's total liabilities were at $221.67 million at the end of 2025, a 23.9% increase from 2024, and a 60.0% increase since 2019.

In the past 6 years, Pharming Group's cash and equivalents has ranged from $54.94 million in 2024 to $207.34 million in 2022, and is currently $145.31 million as of their latest financial filing in 2025.

Over the last 7 years, Pharming Group's book value per share changed from 0.00 in 2018 to 0.41 in 2025, a change of 40.7%.


Related Companies

Financial statements for NASDAQ:PHAR last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
He Called NVIDIA at $1.10 – Now He Says, “SELL”
The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...
The Oxford Club | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
No. You’re not imagining it…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Live demo of Elon Musk’s AI agent
Jeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...
Brownstone Research | Sponsoredtc pixel
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel